Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections NEW HAVEN, Conn., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...

Melinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™ NEW ORLEANS, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company exclusively focused on developing novel antibiotics to treat serious bacterial infections,...

Tetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016 WATERTOWN, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced eight data presentations at IDWeek 2016, taking place October 26-30 in...